Marketing content

Why invest in STIL

Solving an unmet clinical need - Over 30 million people suffer from disabling hand tremors, the uncontrollable shaking often seen in Parkinson’s disease. Current treatments like medication and surgery are either ineffective, risky, or prone to severe side-effects. The STIL Orthosis reduces forearm tremors by over 80% and provides a safe, practical, and effective solution for daily use.

De-risked medical innovation - The STIL Orthosis is CE-marked, FDA- registered, clinically validated and already on the market in four countries. The technology is protected by patents, securing exclusivity in key markets.

Rapid scale-up potential – STIL relies on a proven distributed sales model involving orthopedic distributors. Since launching in the Netherlands in 2023, the company expanded to Germany (2024), Belgium (2025), and Italy (2025) through key partnerships. This model allows for rapid rollout in new markets, with limited overhead.

Strong financial backing – STIL already raised €3.6 million in funding and is backed by Health Innovations, who is committing up to €500,000 in this financing round.

IJsbrand de Lange, CEO

"At STIL, we are redefining how tremors are treated. The STIL Orthosis is offering a life-changing, non-invasive solution for millions. Our mission is simple: improve the quality of life of those affected with tremor disorders. With CE mark and FDA registration, patented technology, and growing international partnerships, we are ready to scale up.

This funding will accelerate our commercial expansion, invest in our product pipeline, and secure reimbursement in key markets. Now is the opportunity to invest in a proven and scalable medical breakthrough, that will have a world-wide impact.” 

IJsbrand de Lange, CEO & Founder, STIL

Investment information

Days to invest:
30
Investing round ends:
07/05/2025
Type:
Equity offering
Invested so far:
€586,353.80
Equity offered:
6.36 – 19.23 %
Price per share:
€58.46
min investment 5 shares
Transaction costs:
1.50 %
Number of existing shares:
162,500
Fully diluted shares:
171,054
Pre-money valuation:
€10,000,000.00
Maximum issue size:
€2,999,874.90
Offered units:
51,315
Broker:
Oneplanetcrowd International B.V
License:
ECSPR

Overview

Company profile

STIL team

A new way to treat tremors
Founded in 2017 in Delft, the Netherlands, STIL is revolutionizing tremor treatment with its innovative, non-invasive medical device: the STIL Orthosis. Designed for people suffering from essential tremors, dystonia and Parkinson’s disease, STIL’s device can reduce forearm tremors by more than 80%, restoring people’s independence and enabling activities of daily life.

Clinically proven technology
In 2022, STIL reached a major clinical milestone, when it successfully completed its first clinical trial. This proved effectiveness for essential tremor patients with a forearm tremor. The study got international acknowledgement, when published in the renowned medical journal Movement Disorders. Several other clinical trials are in progress, expanding the medical claims to Parkinson's disease and other movement disorders.

Medical certification and patent protected
STIL holds an ISO 13485 certification, the most important quality management standard in the medical field. Our product is CE-certified and FDA-registered, allowing us to legally sell in all of the EU and US. We have multiple patents protecting the IP of the STIL Orthosis in key countries across the world.

STIL patents

Proven market traction
By 2024, the company had sold hundreds of devices and established key distribution contracts in the Netherlands, Germany, Belgium, and Italy, expanding its reach across Europe. STIL received €3.6 million in funding from reputable investors, including Health Innovations, Rabobank, EIC Accelerator and the Brain Foundation Netherlands.

By investing in STIL, you are supporting a patented, clinically validated technology that addresses a major unmet medical need while offering strong financial growth potential.

Company Info 

Company name: STIL
Managing director: IJsbrand de Lange
Business ID number: 69993447
Founding year: 2017
Address: Molengraaffsingel 10
2629 JD Delft
Netherlands
Industry: MedTech
Number of employees: 14
Locations: 1
Website: www.stilorthosis.com
Social media:

            

How STIL makes a difference

Only 12% of tremor patient are satisfied with their care
Typically, tremor patients receive off-label medication, such as blood pressure relievers or anti-epileptic medication to reduce tremor. However, both have limited efficacy and severe side-effects. The last resort is brain surgery, though many patients are unwilling to undergo such an invasive procedure. This results in millions of patients not having a proper treatment option.

(below a spiral drawing of a tremor patient and a healthy subject)

Spiral drawing of a tremor patient vs. a healthy subject

Tremors also bring shame
Many people are ashamed of their tremors, resulting in social isolation. A mother not going out for dinner anymore. A teacher not daring to write on the white-board. Or a grandpa who cannot feed his grandchildren. The social aspect is most often just as debilitating as the functional limitations.

Impact of the orthosis
The STIL Orthosis can actually make a night and day difference for tremor patients. In the video below, one of our users highlights its benefits.

Reducing healthcare costs
The STIL Orthosis can be an alternative to expensive medication or surgery. With proper adoption in the regular care path, we estimate to be able to save €100 million per year in the EU alone. This is an incentive for Health Insurers to reimburse the product.

Products and Services

STIL anti-tremor orthosis 
STIL developed a revolutionary anti-tremor orthosis: a wearable device that mechanically stabilizes the arms. The device adds mechanical damping to the joints in the forearm, reducing tremors while allowing voluntary movement. Unlike existing treatment options that rely on medication, surgery, or electrical stimulation, STIL’s solution is non-invasive, requires no electricity and provides immediate relief. The device is designed for ease of use – even 90-year-old users can put it on independently.

Woman with tea

Modular device 
The STIL Orthosis is a modular device, with different sized modules for the hand, forearm, and elbow. In this way, the device can be configured to the correct fit for each user, allowing for optimal user comfort. Modules are also symmetric, meaning they can be configured for either right or left arm use, which greatly reduces the number of parts needed in stock. 

Modular device

Product pipeline 
After over 375 tests with tremor patients, we learned how to improve the product. Where the current orthosis helps people with predominantly forearm tremors, our next-generation orthoses (yes - plural) aim to reduce tremors in the entire arm. Our data shows this should at least double the market potential. STIL filed another patent on this technology, and expect to add 2 more, securing IP of this innovation. The product launch for the next generation is planned for 2026. Beyond tremors, we are exploring how our orthotics can serve as a platform for treating movement disorders more broadly. 

Product

Business model

New innovation, existing sales network.
STIL brings a breakthrough innovation into an existing sales network. We sell (B2B) our products to specialized orthopedic and prosthetic (O&P) distributors. They have an established role in the healthcare supply chain, and work directly with hospitals and health insurers. With a prescription from a medical specialist, they take care of the paperwork needed for reimbursement, and provide the orthosis to the patient

Business strategy

Go-to-market strategy
To jumpstart each partnership, we initially provide distributors with potential customers (‘Leads”), which we obtain from online ads. This helps to understand the product, the target group, and drives initial direct-to-consumer sales. In parallel, when entering a new market, we together start working on reimbursement. With reimbursed care, STIL anticipates a sharp increase in sales volume and improved accessibility for patients. Recurring revenue is expected every 2-3 years, with new product(s) – some users even have two for both arms – being sold.

Collaboration

Ottobock

Key partnerships and rapid scalability
STIL’s distribution model is built for fast international growth. In less than 2 years, we launched in 4 countries. STIL has already made partnerships with renowned O&P distributors, such as Ottobock in Italy, Sanitätshaus STOLLE in Germany, and VIGO in Belgium. New partnerships in Europe and the US are already in the pipeline. The model supports rapid rollout across markets, while maintaining strong margins.

Market

Lady wearing the STIL orthosis

Market size: Over 30 million people suffer from tremors worldwide, most being dissatisfied with current treatments. In the EU and US alone, STIL’s serviceable addressable market (SAM) is estimated at €3 billion. The market is also growing, driven by an aging population and rising incidence of neurological disorders. Parkinson’s cases have doubled in 25 years, and essential tremor affects nearly 6% of people over 65.

Competitive landscape: Traditional treatment options include medication, deep brain stimulation (DBS) and High Intensity Focused Ultrasound (HIFU). DBS is a costly (~€40,000) and invasive brain surgery, HIFU creates permanent brain damage, while pharmaceutical treatments often have limited effectiveness and side effects. Another wearable solution provides 50% tremor reduction, take almost an hour to have any effect, and can only be used for limited time. STIL’s orthosis is clinically proven to reduce forearm tremors over 80%, provides instant relief and is comfortable and easy to use, giving a clear advantage over current treatment options.

Barriers to entry: Entering this market requires clinical proof, regulatory approval, and deep technical know-how. STIL holds a first-mover advantage with CE marking, FDA registration, and patented technology. Competitors wishing to enter the same space face high development costs and long timelines – especially for clinical trials that take years to complete, and cannot be rushed, regardless of funding. Replicating STIL’s performance is not only technically difficult, but mostly time-intensive. With continuous innovation and launch of new products, STIL will keep this first-mover advantage.

People cheers

Lady painting

Impact

The Sustainable Development Goals (SDGs or 'Global Goals') are part of the UN 2030 Agenda for Sustainable Development and constitute the international framework for sustainable development until 2030. These SDGs are intended to put an end to poverty, inequality, and climate change.

SDG3

SDG 3: Good Health and Well-Being
STIL is committed to improving the quality of life for millions of people affected by tremors. By providing a clinically proven, non-invasive solution, STIL helps patients regain their independence and perform everyday activities such as eating, writing, and drinking with ease. The company’s technology eliminates the risks associated with invasive surgical procedures and long-term medication use, offering a safer and more effective alternative for managing tremors. Through continuous research and development, STIL contributes to advancements in healthcare accessibility and innovative medical treatments.

SDG9

SDG 9: Industry, Innovation, and Infrastructure
STIL is pioneering next-generation medtech solutions to address an urgent healthcare need. Its patented fluid damper technology provides a scalable, accessible alternative to traditional tremor treatments. By collaborating with leading medical distributors and research institutions, STIL drives medical innovation while expanding its market reach. Its expansion into new territories strengthens healthcare infrastructure and supports technological advancements in the industry.

SDG10

SDG 10: Reduced Inequalities
The orthosis empowers people with motor disabilities (tremor) to regain autonomy and participate more fully in society, reducing the functional limitations that can cause social exclusion.

SDG12

SDG 12: Responsible Consumption and Production
Sustainability is a core principle in STIL’s product design. The durable and repairable orthosis is built to last, reducing the need for frequent replacements and minimizing medical waste. Unlike many medical devices, STIL’s orthosis does not require electricity, lowering energy consumption and contributing to a more sustainable healthcare system. The company is committed to responsible manufacturing practices, ensuring that materials and production processes meet high sustainability standards.

Management

  

Ijsbrand de Lange, CEO

IJsbrand de Lange

CEO & Founder

IJsbrand is a visionary leader with an entrepreneurial mindset. After his studies biomechanical engineering (TU Delft), he founded STIL in 2017. Since then, he has led the company through both challenges (such as technological pivots and the COVID pandemic) and milestones (product launch), ensuring that product development was always aligned with users, and growth plan. As the CEO of STIL, he oversees general business strategy, fundraising, (clinical) operations, and scaling the company. He raised over €6 million in funding, designed clinical studies, and is in charge of contracting distributors. It is his mission to make STIL a global player in treating movement disorders, and he has the perseverance and skill-set to make this a reality

  

Nicola Pambakian, CTO

Nicola Pambakian

CTO & Co-Founder

Nicola spent over 10 years in the R&D sector, before joining STIL as CTO in 2019. He obtained key skills in product development and management of medical technology when he was Lead Engineer at a startup developing an automatic prosthetic knee. Nicola is a methodical and structured engineer and manager, keen on details, and has a user-centered mindset. Without prior experience, Nicola single-handedly took care of all certification (CE, FDA, ISO 13485) for the company, managed the patent strategy and portfolio, and is overseeing R&D development on daily basis. Like all other team members, he did not join STIL for the money, but because of the meaning and importance of STIL’s mission.
 

With this financing round, STIL aims to expand the management team with experienced commercial and operations director (CCO/COO) and medical or scientific director (CSO/CMO). This is needed to add commercial and clinical competence to the company, needed for scaling up sales, and facilitate obtaining healthcare reimbursement on an international level.

Board of advisors

  

Cees Zuiderwijk

Cees Zuiderwijk

Former VP of Sales Bioness 

Cees Zuiderwijk has over 40 years of experience in selling medical technology to distributors. At Enraf-Nonius, he led the global expansion in rehabilitation equipment. At Bioness, he was responsible for introducing neuromodulation products like the H200 (arm orthosis) in the US and EMEA. He brings deep knowledge of go-to-market strategies, reimbursement of orthotics, distributor networks, and scaling medtech solutions internationally.

  

Bart van Liebergen

Bart van Liebergen

Former CEO Livit Orthopedie / Private Equity

Bart van Liebergen began his career in private equity before becoming CEO of Livit Orthopedie, the largest orthopedic and prosthetic service provider in the Netherlands. There, he worked closely with manufacturers and led the company through a successful sale to private equity. At Stöpler Medical, he repeated this trajectory of scaling the business and managing its acquisition. Bart brings a strong track record in commercial strategy, and value creation leading up to exits.

Distribution of company shares

STIL Group B.V. is currently owned by 4 shareholders:

  • Founders (71%): A significant portion of shares is held by the two founders, reinforcing their commitment to long-term success.
  • Health Innovations (24%): Holds an equity stake following its investment in STIL’s seed round.
  • Brain Foundation Netherlands (5%): Holds warrant shares that can be converted prior to an exit for ordinary shares. This foundation does not yet hold any actual shares, and thus has no voting rights.

Company structure

Where are you investing in?

Investors in this funding round will participate via Stichting Administratiekantoor (‘STAK’) STIL, a foundation set up to issue depository receipts linked to shares in STIL Group B.V. This structure allows investors to indirectly hold an economic interest in STIL Group B.V. In case of a maximum round, the share distribution will change according to the below stated image.

STIL company structure

STIL Group B.V. oversees all strategic operations of its subsidiaries, and is 100% owner of STIL B.V., the entity where all operational activities and expenses are born (such as personnel, marketing, sales, R&D). Profits generated by STIL B.V. from product sales are reinvested into product development, market expansion, and operational growth. All immaterial capital expenses, such as patents, are born by STIL Group B.V.

Health Innovation SEED Fund III B.V. is governed by Venture Capiral firm Health Innovations. De Hersenstichting (Brain Foundation Netherlands) is a warrant holder of shares of STIL Group B.V.

Investment protection
The depository receipts of STAK STIL are linked to a preference share class of STIL Group B.V. that have several financial protection clauses. Most notably:

  • Anti-dilution clause (broad-based weighted-average): if a future financing round occurs at a lower valuation, the conversion price of existing depository receipts will be adjusted using a broad-based weighted-average formula. This ensures that early investors are partially protected from dilution, maintaining a fair pro-rata share relative to the total fully diluted capital base.
  • Liquidation preference: at moment of liquidation, such as an exit, the depository receipts are either sold at 1x the buy-value plus 10% accumulating dividend per year, or converted to ordinary shares and sold in a pro-rata distribution – whichever of the two has the highest return.

These clauses make sure Investors are fairly protected in down-rounds or when an exit is below expectations.

Use of funds

This funding round will be primarily used to scale up sales and operations to the EU and US, but also to launch a second generation of orthoses to the market. In general, it will be spent on the following key areas:

  1. Market Expansion and Sales Acceleration – Contracting new distributors in Europe and North America, that are already in the pipeline. We need to expand the team with additional marketing and sales personnel to support such scaling efforts. In addition, we will invest more in marketing, both directly to potential users via online ads, and engaging with doctors via key congresses.
  2. Product Development – Advancing next-generation orthoses, expanding beyond tremors in the forearm, and even to other movement disorders. Part of the funds will be used to strengthen the company's IP portfolio.
  3. Clinical & Regulatory – Investing in several clinical trials to obtain strategical scientific and medical evidence to supports healthcare reimbursement claims in key countries. In addition, obtain regulatory approval for the UK, AU and JP.
  4. Operational Scaling – Increasing manufacturing capacity, acquiring adequate operational software, including an ERP system, and streamlining logistics to meet growing product demand. Furthermore, we aim to reduce the cost price of the orthosis by 40-60%, by investing in injection molding production, optimization of materials and design, and supplier selection. We modelled two scenarios (high and low) to provide an additional insight in business strategy and allocating of budget

We modelled two scenarios (high and low) to provide an additional insight in business strategy and allocating of budget.


Icon 1

Maximum Scenario

(€3 million collected in the financing round, €2.5 million by crowd investors, €500,000 by Health Innovations)

  • 40% Market Expansion & Sales Acceleration: Launching in all target countries (EU + US) like originally anticipated. Multiple countries start in parallel, overseen by a senior commercial director.
  • 30% Product Development: Speed up R&D with equipment and personnel, with the aim of launching the next generation device in 2026.
  • 15% Regulatory & Compliance: Investing in clinical studies to speed up the path to reimbursement, managed by a seasoned clinical director.
  • 15% Operational Scaling: Investing in software, and hiring additional operational staff to support further and accelerated commercialization.

Icon 2

Minimum Scenario

(€1.0 million collected in the financing round, €700k by crowd investors, €300,000 by Health Innovations) 

  • 60% Market Expansion & Sales Acceleration: In this scenario, STIL will focus entirely on commercialization in the EU, starting with getting full coverage in Germany, in which the company already has considerate market traction. Expansion to new territories will be executed one step at a time.
  • 30% Product Development: The development of a second-generation device will be completed and launched in a controlled manner.
  • 10% Operational scaling: investing in operational software tools to optimize the supply chain.

In this scenario, we reduce high-capital endeavors like entering the U.S., and major one-time capital expenditures, such as clinical studies and injection molding, and keep the team at a minimum size, until STIL reaches break-even or secures additional financing.

In the situation where capital is raised in between the two scenarios, the funds will be spent appropriately and accordingly on the 4 key-areas while keeping a healthy liquidity buffer for any setbacks.

Financial figures & growth

Actual and planned figures

Get an insight into STIL's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Login Sign up

Valuation

Icon Money

STIL's pre-money valuation for this financing round is set at €10 million, based on key milestones achieved since the previous investment. This valuation is further supported by a reverse-calculated exit scenario aligned with a target IRR. The current VC’s decision to invest under the same terms reinforces confidence in this valuation, supporting the growth potential of STIL.

Key milestones achieved

In June 2022, STIL was valued at €5 million post-money, based on a €250,000 investment for 5% equity. Since then, STIL has achieved various major milestones, including:

  • CE and FDA registration STIL Orthosis.
  • US patent granted.
  • EIC Accelerator grant (€1.6 million + 3 million optional equity), for product development of the next generation orthosis. The equity could be used in follow-up financing rounds.
  • Product-market fit: Product launch and revenue growth of 118% YoY.
  • Successfully concluded a clinical study, later published in renowned medical journal Movement Disorders.
  • Expansion of sales into Germany, Belgium and Italy via distribution partnerships

Pre-money calculation
By working backwards from a probable exit value, ensuring it aligns with an expected return on investment (ROI), the pre-money valuation can be estimated at the current financing round. When assuming no subsequent financing round, an IRR of 35%, an exit in 3-4 years, a revenue multiple of 4-5 on the expected revenue in 2027/2028, and a current financing round of €3 million, the conservative pre-money valuation ranges between €9.5-15.3 million.

Exit scenarios

With this financing round, STIL aims to become a profitable and self-sustaining company. Management expects this milestone could be reached as early as 2027, though 2028 is more likely. By that time, reimbursement coverage of the STIL Orthosis is expected to be secured in key markets, which is typically a major driver for stable revenue growth – and strategic acquisition potential.
 

Icon 1

Scenario 1: Trade Sale (3-5 years)
STIL is an attractive acquisition target for large medical device manufacturers looking to expand their neurology portfolio. With the rising prevalence of neurological disorders and the ongoing unmet need for effective treatments, a clinically validated solution like the STIL Orthosis offers strategic value. An acquisition by a major medtech player could deliver a high-value exit for investors within 3-5 years.

Icon 2

Scenario 2: IPO (4-7 years)
With continued international expansion, strong revenue growth, and increasing market share, STIL could pursue an initial public offering (IPO) within 4-7 years. An IPO would allow investors to exit via public markets while providing STIL with additional capital to scale operations globally.

Icon 3

Scenario 3: Private Equity Buyout (4+ years).  As STIL scales and achieves significant market penetration, private equity firms may seek to acquire the company for portfolio expansion. A buyout could offer investors a profitable return while positioning STIL for further growth under a larger financial entity.


-----End of marketing content-----

Documents

Investment related documents

Log in for more information.

Updates

There are currently no updates available.

This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter.

Invesdor is a Eurocrowd platform member.

Ausgezeichnet als Top-Innovator 2021

Winner of the Golden Bull as the best
Crowdfunding platform 2023.

ECSP lizensiert

Invesdor is licensed under the
ECSP regulation of the EU.